OS in MRD-evaluable patients treated with ivosidenib + azacitidine according to MRD status (n = 33). (A) OS in MRDneg vs MRDpos patients. (B) OS in patients with MRD<1% vs patients with MRD≥1%. NE, not evaluable.
Figure 5.

OS in MRD-evaluable patients treated with ivosidenib + azacitidine according to MRD status (n = 33). (A) OS in MRDneg vs MRDpos patients. (B) OS in patients with MRD<1% vs patients with MRD≥1%. NE, not evaluable.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal